Rhythm Pharmaceuticals, Inc. Basic Information, Manufacturing Base, Sales Area, and Competitors
|
Sr. No. |
Item |
Description |
|
1 |
Company Name |
Rhythm Pharmaceuticals, Inc. |
|
2 |
Website |
rhythmtx.com |
|
3 |
Established Date |
2008 |
|
4 |
Headquartered |
United States |
|
5 |
Market Position/ History |
Rhythm Pharmaceuticals, Inc. is headquarters is in Boston, MA. The company operates in the UK, Ireland, France, Italy, Canada, the US and the Netherlands, among others. |
|
6 |
Sales Area |
Worldwide |
|
7 |
Manufacturing Location |
United States |
|
8 |
Ticker |
NASDAQ: RYTM |
|
9 |
No. of Employees |
177 employees (as of January 31, 2023) |
|
10 |
Competitors |
NexImmune, Aileron Therapeutics, Regulus Therapeutics, Mesoblast, and Alnylam Pharmaceuticals |
|
11 |
CEO |
Dr. David Meeker |
|
12 |
Ownership Type |
Public |
|
13 |
Contact Information |
222 Berkeley Street, 12th Floor, Boston, MA 02116, US |
Business Segment/ Overview:
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company in its commercial stage is dedicated to improving the quality of life for individuals and their families affected by uncommon neuroendocrine disorders. IMCIVREE (setmelanotide), the lead product of Rhythm, is an MC4R agonist that is intended to treat hyperphagia and severe obesity. It has been approved by the FDA for the treatment of chronic weight management in adult and pediatric patients 6 years of age and older who have been diagnosed with Bardet-Biedl syndrome (BBS) or monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency verified by genetic testing.
Setmelanotide has been approved by the European Commission (EC) and the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) for the treatment of obesity and appetite control in individuals who have genetically confirmed BBS or loss-of-function biallelic POMC, including biallelic LEPR deficiency or PCSK1 deficiency, in adults and children aged six and up. Rhythm is also advancing a preclinical small chemical suite for the treatment of congenital hyperinsulinism and a wide clinical development program for setmelanotide in other uncommon disorders.
Anti-Obesity Drugs Product Types Specification
|
Product |
Product Description |
|
IMCIVREE (setmelanotide) Indication |
In the United States, IMCIVREE is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to: Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) Bardet-Biedl syndrome (BBS) Limitations of Use IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign Other types of obesity not related to POMC, PCSK1 or LEPR deficiency, or BBS, including obesity associated with other genetic syndromes and general (polygenic) obesity |
Recent Developments:
|
Year |
Latest News |
|
January 4, 2024 |
Rhythm Pharmaceuticals and LG Chem Life Sciences Entered Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640 In January 2024, Rhythm Pharmaceuticals, Inc. announced it has entered into a global licensing agreement with LG Chem, Ltd. ("LG Chem"), which specializes in life sciences as one of its core businesses, for LB54640, an investigational oral small molecule melanocortin-4 receptor (MC4R) agonist now in Phase 2 clinical trials. |
Author's Detail:
Sneha Mali /
LinkedIn
Sneha Mali is a research analyst working in various domains including the Consumer Goods, market research and transport & logistics and her primary responsibility is to conduct thorough research on various subjects and provide valuable insights to support client requirements. Her knowledge of research methodologies, and data mining which enables me to analyze large data sets, draw meaningful conclusions, and communicate them effectively.Sneha stay up-to-date with the latest research trends, methodologies, and technologies to ensure that her research is accurate, relevant, and impactful.
In her current role, Sneha is committed to continuous learning and staying abreast of emerging trends in research methodologies. Regular participation in workshops, webinars, and industry conferences ensures that her skills remain sharp and relevant. She have demonstrated ability to transform complex data sets into clear and concise narratives that inform key business strategies. Collaborating with cross-functional teams.Sneha remains an invaluable asset in the dynamic landscape of market research.